Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG (NYSE: NVS) has agreed to expand its fill-and-finish support for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine. Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.

Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines

BioNTech SE

Novartis AG said Thursday that it has signed a new agreement with BioNTech SE to support the production of the company's and Pfizer Inc.'s Covid-19 vaccine at one of its facilities.

Novartis signs new agreement with BioNTech to help manufacture COVID vaccines

Basel, October 19, 2021 – Global Heart Hub and Novartis today announced the launch of the Invisible Nation program. Invisible Nation will bring together a worldwide network of patient organizations and other stakeholders in the cardiovascular (CV) space committed to effecting systemic change in the management of atherosclerotic cardiovascular disease (ASCVD). The program aims to prevent many of the 15 million yearly ASCVD deaths1 and reduce what could soon become $1 trillion in annual CV disease cost2.

Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world's #1 killer

Hasbro

QUALCOMM

These stocks are all trading near their 52-week lows, but they're all solid investments to hold over the long term.

3 No-Brainer Stocks to Buy Right Now

Atmos Energy

Colgate-Palmolive

Johnson & Johnson

Kimberly-Clark

The debt ceiling crisis has helped cause a healthy pullback but could result in a 10% to 20% correction in the next few weeks.

5 High-Yield Dividend Aristocrats That Are Perfect For Sinking Markets

AbbVie

British American Tobacco

Cardinal Health

Chevron

Imperial Brands PLC

Leggett & Platt

Red Electrica Corp SA

Swiss Re AG

AT&T

Unilever

V.F.

Exxon Mobil

Kiplinger "insights for investors" online first offered a list of 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 102 Top Dividend Stocks list 7/1/21. 39 European “Dividend Aristocrats” showed 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats showed 25 years of increases for U.S. companies.

Here's 14 Top Dividends On Earth At Ideal Prices For October

Basel, September 30, 2021 — At its eighth annual ESG investor event hosted today, Novartis shared progress against its Environmental, Social and Governance (ESG) targets and updated on its most material ESG topics, including access to medicines, patient health and safety, innovation and ethical standards.

Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions

Altria

National Retail Properties

The 28% overvalued market is priced for nothing ever going wrong again. Today there are nine risks that could bring about a 10% to 20% correction. The biggest short-term risk is the debt ceiling drama that economists such as Moody's think could bring about another Great Recession.

3 No-Brainer High-Yield Dividend Aristocrat Buys During This Market Slide

Novartis AG (NYSE: NVS) announced data from an international Phase 3b study of Cosentyx (secukinumab) in plaque psoriasis. Data showed that treatment with Cosentyx 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high efficacy and convenient administration.

Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis

The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer.

This Potential Indication Could Be a Winner for Novartis

Horizon Pharma

Eli Lilly

Merck

Regeneron Pharmaceuticals

These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.

7 Biotech Stocks Entering the Golden Boom Phase

Diageo

Sanofi

With September and the third quarter almost over, many investors are looking to the fourth quarter and beyond.

5 European Dividend Aristocrats Offer Huge Income and Growth Potential

Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos' proprietary technology to its ophthalmology portfolio.  Deal terms were not disclosed.

Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition

Novartis has bought gene therapy specialist Arctos Medical to boost its efforts finding treatments for patients with severe vision loss, the Swiss company said on Tuesday.

Novartis buys gene therapy company Arctos Medical

Deutsche Bank has downgraded Novartis AG (NYSE: NVS) to Sell from Hold with a price target of CHF 70, down from CHF 80.  Analyst Emmanuel Papadakis sees "grounds for outright caution near term" with Opthalmology looking structurally challenged.

Why Did Deutsche Bank Downgrade This Big Pharma Stock?

Novartis AG (NYSE: NVS) announced results of the final overall survival (OS) analysis of Phase 3 MONALEESA-2 study, which evaluated Kisqali (ribociclib) in combination with letrozole in breast cancer patients. The trial compared the combination therapy to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease.

Novartis' Kisqali Combo Therapy Extends Survival By One Year In Breast Cancer Patients

The digital press release with multimedia content can be accessed here:

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and improved signs and symptoms in pediatric and adult patients. Results were presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021 [LBA23].

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)

Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology Congress 2021 ( ESMO21 ) presented the therapy's effect on the quality of life and pain.

Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life

Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. Many patients with mCRPC live with reduced physical functioning as well as significant pain2,3. This data from a quality of life assessment of the VISION trial, referred to as HRQoL, showed delayed worsening of these difficult to bear symptoms in the 177Lu-PSMA-617 plus standard of care arm compared to standard of care alone arm. No new or unexpected safety concerns, including changes in creatinine clearance, were noted1. These results will be presented at the European Society for Medical Oncology (ESMO) Congress, 17-21 September 2021.

Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Baxter

Con Ed

Hormel Foods

Kellogg

Northwest Natural Gas

Pinnacle West Capital

Reckitt Benckiser Group PLC

Verizon

The market is 30% overvalued, and September is historically a time when many corrections begin. Fortunately, there are plenty of high-yield/low volatility blue chips to choose from.

14 High-Yield Blue Chips For A Rich Retirement

International stocks tend to offer higher yields than their U.S.-based counterparts, and also offer geographic diversification. The post 3 International Stocks to Buy for Dividend Growth appeared first on InvestorPlace.

3 International Stocks to Buy for Dividend Growth

Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients. The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatment in preventing organ rejection.

Novartis Stops Iscalimab Trial In Kidney Transplant Patients

The U.K. government, NHS England, and Novartis AG (NYSE: NVS) unveiled a "world-first" reimbursement deal for providing broader access to anti-cholesterol drug Leqvio (inclisiran) after the U.K.'s healthcare cost agency NICE approved the medicine. The news follows the January 2020 announcement of the deal parameters.

Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio

Novartis AG has reached a deal to provide its cholesterol-lowering medicine Leqvio to patients via the U.K.'s National Health Service, the Swiss pharmaceutical company said Wednesday.

Novartis to provide cholesterol-lowering drug Leqvio to 300,000 U.K. patients

News for Novartis Stock (NVS)